PMID- 37772585
OWN - NLM
STAT- MEDLINE
DCOM- 20231023
LR  - 20231023
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 43
IP  - 10
DP  - 2023 Oct
TI  - Immunological Responses Associated With Neoadjuvant Therapy in the Tumor 
      Microenvironment of Esophageal Squamous Cell Carcinoma.
PG  - 4691-4700
LID - 10.21873/anticanres.16665 [doi]
AB  - BACKGROUND/AIM: Development of multidisciplinary therapies including immune 
      checkpoint inhibitors for esophageal squamous cell carcinoma (ESCC) requires a 
      clear understanding of immunological responses induced by chemotherapy 
      with/without radiotherapy in the tumor microenvironment. PATIENTS AND METHODS: 
      This is a retrospective analysis of paired pretreatment biopsy samples and 
      surgically resected tumor samples of 49 patients who underwent radical surgery 
      for ESCC with/without neoadjuvant therapy at Fukushima Medical University 
      Hospital. The cohort included 30 patients treated with neoadjuvant chemotherapy 
      (NAC), 11 treated with neoadjuvant chemoradiotherapy (NACRT), and eight who 
      underwent surgery alone and did not receive neoadjuvant antitumor therapy. 
      Chemotherapy included fluoropyrimidine- and platinum-based agents in all treated 
      patients, and radiotherapy included 40 or 42 Gy administered in 20 or 21 
      fractions. Expression of CD8, human leukocyte antigen (HLA) class I-ABC, PD-L1, 
      PD-L2, CEACAM-1, LSECtin, and p-STAT1, were determined using 
      immunohistochemistry. RESULTS: The frequency of tumor-infiltrating CD8(+) T cells 
      was significantly increased by NAC (p<0.05), and the expression of HLA class 
      I-ABC on tumor cells was significantly increased by NAC and NACRT (p<0.05). 
      Furthermore, the ESCC cells expressed PD-L1, PD-L2, and CEACAM-1, whereas the 
      expression of PD-L1 on ESCC cells was significantly correlated with the 
      expression of p-STAT1 in ESCC cells (p<0.05). CONCLUSION: NAC and NACRT induced 
      both positive and negative immunological responses in patients with ESCC. These 
      results may be a part of basis for multidisciplinary therapy including immune 
      checkpoint inhibitors for patients with advanced ESCC.
CI  - Copyright (c) 2023 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Takehara, Yuka
AU  - Takehara Y
AD  - Department of Radiation Oncology, Fukushima Medical University School of 
      Medicine, Fukushima, Japan.
FAU - Tamaki, Tomoaki
AU  - Tamaki T
AD  - Department of Radiation Oncology, Fukushima Medical University School of 
      Medicine, Fukushima, Japan.
FAU - Mimura, Kosaku
AU  - Mimura K
AD  - Department of Gastrointestinal Tract Surgery, Fukushima Medical University School 
      of Medicine, Fukushima, Japan.
AD  - Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical 
      University School of Medicine, Fukushima, Japan.
FAU - Saito, Katsuharu
AU  - Saito K
AD  - Department of Radiation Oncology, Fukushima Medical University School of 
      Medicine, Fukushima, Japan.
FAU - Neupane, Prajwal
AU  - Neupane P
AD  - Department of Gastrointestinal Tract Surgery, Fukushima Medical University School 
      of Medicine, Fukushima, Japan.
FAU - Tada, Takeshi
AU  - Tada T
AD  - Department of Gastrointestinal Tract Surgery, Fukushima Medical University School 
      of Medicine, Fukushima, Japan.
FAU - Watanabe, Yohei
AU  - Watanabe Y
AD  - Department of Gastrointestinal Tract Surgery, Fukushima Medical University School 
      of Medicine, Fukushima, Japan.
FAU - Hayase, Suguru
AU  - Hayase S
AD  - Department of Gastrointestinal Tract Surgery, Fukushima Medical University School 
      of Medicine, Fukushima, Japan.
FAU - Saze, Zenichiro
AU  - Saze Z
AD  - Department of Gastrointestinal Tract Surgery, Fukushima Medical University School 
      of Medicine, Fukushima, Japan.
FAU - Yoshimoto, Yuya
AU  - Yoshimoto Y
AD  - Department of Radiation Oncology, Fukushima Medical University School of 
      Medicine, Fukushima, Japan.
FAU - Sato, Hisashi
AU  - Sato H
AD  - Department of Radiation Oncology, Fukushima Medical University School of 
      Medicine, Fukushima, Japan.
FAU - Kono, Koji
AU  - Kono K
AD  - Department of Gastrointestinal Tract Surgery, Fukushima Medical University School 
      of Medicine, Fukushima, Japan.
FAU - Suzuki, Yoshiyuki
AU  - Suzuki Y
AD  - Department of Radiation Oncology, Fukushima Medical University School of 
      Medicine, Fukushima, Japan ysuzu@fmu.ac.jp.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Humans
MH  - *Esophageal Squamous Cell Carcinoma/pathology
MH  - Neoadjuvant Therapy/methods
MH  - *Esophageal Neoplasms/drug therapy/pathology
MH  - B7-H1 Antigen/metabolism
MH  - CD8-Positive T-Lymphocytes
MH  - Retrospective Studies
MH  - Tumor Microenvironment
MH  - Immune Checkpoint Inhibitors/pharmacology
MH  - Prognosis
OTO - NOTNLM
OT  - CD8
OT  - Esophageal cancer
OT  - HLA class I
OT  - neoadjuvant treatment
EDAT- 2023/09/29 12:43
MHDA- 2023/10/23 01:18
CRDT- 2023/09/29 07:31
PHST- 2023/07/29 00:00 [received]
PHST- 2023/09/03 00:00 [revised]
PHST- 2023/09/04 00:00 [accepted]
PHST- 2023/10/23 01:18 [medline]
PHST- 2023/09/29 12:43 [pubmed]
PHST- 2023/09/29 07:31 [entrez]
AID - 43/10/4691 [pii]
AID - 10.21873/anticanres.16665 [doi]
PST - ppublish
SO  - Anticancer Res. 2023 Oct;43(10):4691-4700. doi: 10.21873/anticanres.16665.